RT Journal Article
SR Electronic
A1 Sinclair, Heather Q.
T1 The Safety and Tolerability of Betrixaban Therapy
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 2
SP 14
OP 15
DO 10.1177/155989771002007
UL http://mdc.sagepub.com/content/10/2/14.2.abstract
AB The oral direct factor Xa inhibitor betrixaban, at doses of 40 mg, 60 mg, and 80 mg once daily, is safe and well tolerated compared with dose-adjusted warfarin in patients with nonvalvular atrial fibrillation (AF) or atrial flutter. This article presents results from the Phase II, randomized, multicenter EXPLORE-Xa Trial [NCT00742859].